Marketing Antipsychotics to Correctional Facilities: A Review of Pharmaceutical Industry Documents

Abstract

This retrospective qualitative review describes the marketing of antipsychotics by pharmaceutical companies to prisons and jails to increase prescribing. This review relied on internal pharmaceutical industry documents released in litigation and stored in the Drug Industry Documents archive at the UCSF Industry Documents Library. At least two pharmaceutical companies directly marketed antipsychotics to correctional facilities to increase sales, using targeted promotions and indirect “educational” advertising and by seeking control of state advisory boards that made formulary decisions. Further research on how medications are marketed is needed, along with stronger conflict-of-interest policies to reduce industry involvement on advisory boards that approve medications. National regulations that restrict pharmaceutical manufacturers from involvement in formulary decisions and prescribing guidelines would likely improve the provision of health care to people who are incarcerated.

Get full access to this article

View all access options for this article.

References

Bero

(2003). Implications of the tobacco industry documents for public health and policy. Annual Review of Public Health, 24, 267–288. https://doi.org/10.1146/annurev.publhealth.24.100901.140813

Blau

(2019, December 31). Marketing psychiatric drugs to jailers and judges: Drug companies are courting jails and judges through sophisticated marketing efforts. The Atlantic. https://www.theatlantic.com/politics/archive/2019/12/pharmaceutical-companies-are-marketing-drugs-jailers/604264

Bronson

, & Berzofsky

(2017). Indicators of mental health problems reported by prisoners and jail inmates, 2011–12 (NCJ 250612). Bureau of Justice Statistics. https://www.bjs.gov/content/pub/pdf/imhprpji1112.pdf

Dale

(2018, July 23). Pharmaceutical companies to provide free antipsychotic drugs to Maricopa County jails. KJZZ. https://kjzz.org/content/673931/pharmaceutical-companies-provide-free-antipsychotic-drugs-maricopa-county-jails

Eli Lilly and Company. (2002, August 2). Key player playbook [Summary of types of prescribers and what type of marketing opportunities and objectives they provide Lilly; Zyprexa litigation documents]. UCSF Industry Documents Library. https://www.industrydocuments.ucsf.edu/docs/fgbn0217

Hassan

, Senior

, Webb

R. T.

, Frisher

, Tully

M. P.

, While

, & Shaw

J. J

. (2016). Prevalence and appropriateness of psychotropic medication prescribing in a nationally representative cross-sectional survey of male and female prisoners in England. BMC Psychiatry, 16(1), 346. https://doi.org/10.1186/s12888-016-1055-7

Janssen Pharmaceuticals. (1999). Risperdal 2000 business plan summary [Risperdal litigation documents]. UCSF Industry Documents Library. https://www.industrydocuments.ucsf.edu/docs/pnkf0226

Janssen Pharmaceuticals. (2002). Strategic customer group 2003 business plan [Oklahoma opioid litigation documents]. UCSF Industry Documents Library. https://www.industrydocuments.ucsf.edu/docs/frgg0230

Lemons

(2003). Article on schizophrenia medications in Newark newspaper [Email; Zyprexa litigation documents]. UCSF Industry Documents Library. https://www.industrydocuments.ucsf.edu/docs/sxbn0217

10.

Mayr

(2002, October 17). Zyprexa U.S. business plan—Executive summary [Speaker notes; Zyprexa litigation documents]. UCSF Industry Documents Library. https://www.industrydocuments.ucsf.edu/docs/fhbn0217

11.

Pew Charitable Trusts. (2017). Pharmaceuticals in state prisons: How departments of corrections purchase, use, and monitor prescription drugs [Report]. https://www.pewtrusts.org/~/media/assets/2017/12/pharmaceuticals-in-state-prisons.pdf

12.

Pimentel

C. B.

, Donovan

J. L.

, Field

T. S.

, Gurwitz

J. H.

, Harrold

L. R.

, Kanaan

A. O.

, Lemay

C. A.

, Mazor

K. M.

, Tjia

, & Briesacher

B. A.

(2015). Use of atypical antipsychotics in nursing homes and pharmaceutical marketing. Journal of the American Geriatrics Society, 63(2), 297–301. https://doi.org/10.1111/jgs.13180

13.

Sawa

(2014, April 14). Prisoners given powerful drugs off-label, allegedly to ‘control behaviour’. CBC News. https://www.cbc.ca/news/prisoners-given-powerful-drugs-off-label-allegedly-to-control-behaviour-1.2609940

14.

Torrey

E. F.

, Zdanowicz

M. T.

, Kennard

A. D.

, Lamb

H. R.

, Eslinger

D. F.

, Biasotti

M. C.

, & Fuller

D. A

. (2014). The treatment of persons with mental illness in prisons and jails: A state survey [Report]. Treatment Advocacy Center. https://www.treatmentadvocacycenter.org/storage/documents/treatment-behind-bars/treatment-behind-bars.pdf

15.

UCSF Industry Documents Library. (2022). Drug industry documents. https://www.industrydocuments.ucsf.edu/drug

16.

U.S. Department of Justice. (2010, April 27). Pharmaceutical giant AstraZeneca to pay $520 million for off-label drug marketing [Press release no. 10-487]. Office of Public Affairs. https://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing Washington v. Harper 494 US 210 (1990).